Onxeo S.A. announced that the Combined General Meeting held on June 10, 2021. The shareholders of the Company also renewed for three years the mandate of Mr. Thomas Hofstaetter, which expired at the end of this General Meeting and ratified the appointment of Mr. Julien Miara, representing Invus, to replace Mr. Jean-Pierre Kinet until the expiry of his mandate, at the end of the Meeting called to approve the accounts for the year ended December 31, 2021. The appointment of Dr. Shefali Agarwal as a board member, Executive Vice President and Chief Medical and Clinical Development Officer of Epizyme, a US biotech company specialized in oncology, was also approved.